Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Carcinoid Tumor: early-phase trial registry

3 of 9 indexed Carcinoid Tumor trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Carcinoid Tumor: 9 US clinical trials tracked, 3 recruiting.

Carcinoid Tumor is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is CASI pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition carcinoid-tumor

OPEN 3 | RECR 33% | LATE 2 | EARLY 7 | RANK #1916 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Carcinoid Tumor (this)33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Carcinoid Tumor

Carcinoid Tumor lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Carcinoid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Carcinoid Tumor is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Carcinoid Tumor trials is spread across many organizations.

    CASI pharmaceuticals accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Carcinoid Tumor trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.

  4. Carcinoid Tumor research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 26Phase 32

Open and recent trials

9 total, page 1 of 1

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 6
Phase 3 2

Named interventions

Most-linked intervention names on Carcinoid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) Drug
1 trials
Quarfloxin Drug
1 trials
AMG 479 Drug
1 trials
Pharmacological Study Other
1 trials
Nintedanib Drug
1 trials
Paltusotine Drug
1 trials
Octreotide Drug
1 trials
RYZ101 Drug
1 trials

US sites by state

Facility locations filed on Carcinoid Tumor trials. A trial with sites in several states counts in each.

Florida 5 trials
Massachusetts 3 trials
California 3 trials
Texas 2 trials
Pennsylvania 2 trials
Ohio 2 trials
New York 2 trials
Minnesota 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Carcinoid Tumor page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoid Tumor condition card totals 9 registered trials; most-linked intervention Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab); top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.